These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24406434)

  • 1. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease.
    Iskandar HN; Cassell B; Kanuri N; Gyawali CP; Gutierrez A; Dassopoulos T; Ciorba MA; Sayuk GS
    J Clin Gastroenterol; 2014; 48(5):423-9. PubMed ID: 24406434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of Irritable Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of Anxiety and Depression.
    Perera LP; Radigan M; Guilday C; Banerjee I; Eastwood D; Babygirija R; Massey BT
    Dig Dis Sci; 2019 Jul; 64(7):1923-1928. PubMed ID: 30725303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
    Vivinus-Nébot M; Frin-Mathy G; Bzioueche H; Dainese R; Bernard G; Anty R; Filippi J; Saint-Paul MC; Tulic MK; Verhasselt V; Hébuterne X; Piche T
    Gut; 2014 May; 63(5):744-52. PubMed ID: 23878165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The central role of psychopathology and its association with disease severity in inflammatory bowel disease and irritable bowel syndrome.
    Piacentino D; Cesarini M; Badiali D; Pallotta N; Biondi M; Corazziari ES
    Riv Psichiatr; 2019; 54(2):75-83. PubMed ID: 30985832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of residual inflammatory bowel disease symptoms with low-dose tricyclic antidepressants: why not?
    Drossman DA
    J Clin Gastroenterol; 2014; 48(5):390-2. PubMed ID: 24714103
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners.
    Abdalla MI; Sandler RS; Kappelman MD; Martin CF; Chen W; Anton K; Long MD
    Inflamm Bowel Dis; 2017 Feb; 23(2):325-331. PubMed ID: 28092305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease.
    Ahmed M; Pu A; Jencks K; Bishu S; Higgins P; Chey WD; Rao K; Lee A
    Neurogastroenterol Motil; 2024 Jun; 36(6):e14809. PubMed ID: 38651743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis.
    Rahimi R; Nikfar S; Rezaie A; Abdollahi M
    World J Gastroenterol; 2009 Apr; 15(13):1548-53. PubMed ID: 19340896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Guthrie EA; Hamlin PJ; Ford AC
    Gastroenterology; 2018 May; 154(6):1635-1646.e3. PubMed ID: 29366841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypnotherapy for Irritable Bowel Syndrome-Type Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Controlled Trial.
    Hoekman DR; Vlieger AM; Stokkers PC; Mahhmod N; Rietdijk S; de Boer NK; de Meij TG; Frankenhuis C; D'Haens GR; Benninga MA
    J Crohns Colitis; 2021 Jul; 15(7):1106-1113. PubMed ID: 33245332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity.
    Oikonomou KA; Kapsoritakis AN; Theodoridou C; Karangelis D; Germenis A; Stefanidis I; Potamianos SP
    J Gastroenterol; 2012 May; 47(5):519-30. PubMed ID: 22200942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?
    Burgmann T; Clara I; Graff L; Walker J; Lix L; Rawsthorne P; McPhail C; Rogala L; Miller N; Bernstein CN
    Clin Gastroenterol Hepatol; 2006 May; 4(5):614-20. PubMed ID: 16630762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis.
    Halpin SJ; Ford AC
    Am J Gastroenterol; 2012 Oct; 107(10):1474-82. PubMed ID: 22929759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anhedonia in irritable bowel syndrome and in inflammatory bowel diseases and its relationship with abdominal pain.
    Carpinelli L; Bucci C; Santonicola A; Zingone F; Ciacci C; Iovino P
    Neurogastroenterol Motil; 2019 Mar; 31(3):e13531. PubMed ID: 30628137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
    von Stein P; Lofberg R; Kuznetsov NV; Gielen AW; Persson JO; Sundberg R; Hellstrom K; Eriksson A; Befrits R; Ost A; von Stein OD
    Gastroenterology; 2008 Jun; 134(7):1869-81; quiz 2153-4. PubMed ID: 18466904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.
    Simrén M; Axelsson J; Gillberg R; Abrahamsson H; Svedlund J; Björnsson ES
    Am J Gastroenterol; 2002 Feb; 97(2):389-96. PubMed ID: 11866278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
    Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
    World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.